Clinical Importance of Drug Adherence during Tyrosine Kinase Inhibitor Therapy for Chronic Myelogenous Leukemia in Chronic Phase

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm constituting approximately 15% of newly diagnosed leukemia in adult patients. Development of tyrosine kinase inhibitors (TKIs) have dramatically improved outcomes in patients with chronic CML in chronic phase. However, adverse drug even...

Descrición completa

Detalles Bibliográficos

Principais autores:	Yasuhiro Maeda, Atsushi Okamoto, Kenta Yamamoto, Go Eguchi, Yoshitaka Kanai
Formato:	Artigo
Idioma:	Inglês
Publicado:	MDPI AG 2019-10-01
Series:	Reports
Assuntos:	chronic myeloid leukemia tyrosine kinase inhibitor adverse drug event quality of life second-generation tyrosine kinase inhibitor nilotinib
Acceso en liña:	https://www.mdpi.com/2571-841X/2/4/25
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!